OKYO Pharma Limited Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.12next fiscal year
Monitoring Framework
Key Performance Indicators
Urcosimod (OK-101) Phase 2b/3 NCP Trial EnrollmentTarget: 150 patients
Cash and Cash Equivalents Quarterly4.2MTarget: Sufficient runway for Phase 2b/3 trial
Watch Items
- Initiation of the 150-patient multiple-dose Phase 2b/3 trial of urcosimod in Neuropathic Corneal Pain (NCP)Trigger: First patient dosed (expected 1H 2026)Action: Monitor press releases and SEC Form 6-K filings for trial initiation updates.
- Topline clinical data readout for the Phase 2b/3 NCP trialTrigger: Data unmasking and statistical analysis completion (expected late 2026)Action: Evaluate efficacy endpoints (VAS pain score reduction at Week 12) and safety profile.
Research as of 19 Jun 2026